The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity

Basit Öğe Kaydı
dc.contributor.authorYavas, C.
dc.contributor.authorYavas, G.
dc.contributor.authorToy, H.
dc.contributor.authorAta, O.
dc.date.accessioned2024-02-23T14:26:58Z
dc.date.available2024-02-23T14:26:58Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractPostmenopausal patients with breast cancer have two options for adjuvant endocrine therapy, tamoxifen and aromatase inhibitors (AIs) as well as radiotherapy (RT) and chemotherapy. However, there is limited data regarding the optimal sequencing of RT and tamoxifen/AIs. Thus, we aimed to evaluate the effects of tamoxifen and AIs on radiation-induced cardiotoxicity. Eighty ovariectomized rats were divided into eight groups (G). G1 was defined as a control group; G2, G3, G4, and G5 were RT, tamoxifen, anastrozle, and letrozole groups, respectively; G6, G7, and G8 were RT plus tamoxifen, anastrozle, and letrozole groups, respectively. Drugs were started 1 week before RT and continued until the animals were killed 16 weeks after RT. The heart tissues were then dissected and examined with light microscopy to determine endocardial thickness and cardiac fibrosis. The endocardial thickness scores of both RT alone and the tamoxifen groups as well as the cardiac fibrosis score of RT alone were higher than that the control group (p < 0.05 for all). There was no difference in the endocardial thickness and cardiac fibrosis scores of the RT-only group and the RT plus hormonotherapy groups (p > 0.05 for all). Concurrent administration of RT and hormonal therapy with either tamoxifen or AIs did not further amplify radiation-induced cardiac toxicity. This issue warrants further study.en_US
dc.description.sponsorshipSelcuk Universityen_US
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by Selcuk University. The study's sponsor had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.en_US
dc.identifier.doi10.1177/0960327116666648
dc.identifier.endpage801en_US
dc.identifier.issn0960-3271
dc.identifier.issn1477-0903
dc.identifier.issue8en_US
dc.identifier.pmid27596072en_US
dc.identifier.scopus2-s2.0-85024111203en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage795en_US
dc.identifier.urihttps://doi.org/10.1177/0960327116666648
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14404
dc.identifier.volume36en_US
dc.identifier.wosWOS:000405495700004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofHuman & Experimental Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAromatase Inhibitorsen_US
dc.subjectCardiac Toxicityen_US
dc.subjectHormonotherapyen_US
dc.subjectRadiotherapyen_US
dc.subjectTamoxifenen_US
dc.titleThe use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu